Pre-made Vedolizumab biosimilar ( Whole mAb, anti-ITGA4_ITGB7 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-616
Anti-ITGA4_ITGB7 therapeutic antibody (Pre-made Vedolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc (currently named Takeda Oncology, a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ITGA4_ITGB7 therapeutic antibody (Pre-made Vedolizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology|
|Conditions Approved||Crohn's disease;Ulcerative colitis|
|Conditions Active||Graft-versus-host disease;Coeliac disease|
|Conditions Discontinued||Malignant melanoma|